Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... the status of the KB001-A development program, including an ... KB001-A Collaboration Update KaloBios ... Pasteur to regain all rights to KaloBios, KB001-A program. ... into in 2010 has been terminated. Under that collaboration ...
(Date:7/28/2014)... RESTON, Va. , July 28, 2014 /PRNewswire/ ... management services, announced the Company has been awarded ... Medical Support Command (NEMSCOM) and its Deployable Medical ... to enable medical personnel to provide world-class healthcare ... any operating environment across the globe. The five ...
(Date:7/28/2014)... 28, 2014  Array BioPharma Inc. (Nasdaq:   ... fourth quarter and full year of fiscal ... discuss those results on Tuesday, August 12, ... Michael Carruthers , Chief Financial Officer ... 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
(Date:7/29/2014)... Oconto Falls, WI (PRWEB) July 29, 2014 ... their third development project, The Cottages at MeadowLands Memory ... the growing population of those suffering from memory loss ... W.M. Enterprises, Inc., has approved the development of Oconto ... memory care. Cara Peterson, GM of The Cottages Investment ...
(Date:7/29/2014)... 29, 2014 Tucson-based company Outski ... benefits package, or health and wellness program, called 401(play)™. ... providing an effective way for employees to use their ... the program, employees specify the amount of each paycheck ... An employer benefits from offering a 401(play)™ plan to ...
(Date:7/29/2014)... latest blog post at http://www.perwickstrom.com , entrepreneur, author, speaker ... ways to light the “fire” in employees. , “Employers are ... some it’s a losing battle,” commented Per Wickstrom . ... employees get to the next level; which not only helps ... Per Wickstrom, 6 ways to light the “fire” in employees ...
(Date:7/29/2014)... 29, 2014 Launched in 2012 by ... surpassed 20,000 hangovers earlier this year at its Vegas ... expansion and the publication of research data related to ... practice. , The only licensed medical practice dedicated to ... launched in 2012 and treated thousands of patients within ...
(Date:7/29/2014)... July 29, 2014 The Marietta cosmetic ... teeth whitening for high school and college students ... The teeth whitening is a safe, professional strength system, ... better confidence for students at these important stages in life. ... but have never had their teeth whitened. "After braces, ...
Breaking Medicine News(10 mins):Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 3Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 4Health News:Outski launches 401(play)™ Plan to Employers as Part of an Employee Benefit / Health and Wellness Program 2Health News:Per Wickstrom’s Latest Blog Post Lists 6 Ways to Light the “Fire” in Employees 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 3Health News:Back to School Teeth Whitening Extravaganza For High School Students and Collegiates During August 2014 2Health News:Back to School Teeth Whitening Extravaganza For High School Students and Collegiates During August 2014 3
... of patent pending technologies, WELLINGTON, Fla., March ... QGP.WSB) (http://www.QuantumMD.com ) announced today that,the Board ... President and,Chief Executive Officer; have reached an agreement ... things, extend his term of employment,with the Company. ...
... to herbicides and insecticides , , FRIDAY, March 28 (HealthDay ... to pesticides in a new study comparing people with ... The study, published online in the open-access journal ... use of herbicides and insecticides, such as organochlorides and ...
... continuing economic,woes, applying quality initiatives to customer service ... great service to help establish a,premium for product ... new product development. "There is a greater need ... "Using Quality to Improve the Customer Experience," the ...
... A new survey shows that more than,two-thirds of consumers ... recent approval of the Food and Drug Administration., ... percent of,respondents said they were unsure about the safety ... Many respondents referred to,Dolly, the first cloned sheep, and ...
... YORK, March 27 Ten years ago, ... dysfunction launched a revolution in the way ... this report from Pfizer (NYSE: PFE ... can access video, audio, text, graphics and,photos ...
... testing likely contributed to increase , , THURSDAY, March ... United States have increased 123 percent in a decade, ... middle-aged patients, according to new findings. , The increases ... for which data are available. Death rates peaked in ...
Cached Medicine News:Health News:The Quantum Group Extends CEO's Employment Agreement 2Health News:The Quantum Group Extends CEO's Employment Agreement 3Health News:Family Study Associates Pesticide Use With Parkinson's Risk 2Health News:Superior Customer Service Imperative During Economic Downturn 2Health News:Sharp Rise in U.S. Hepatitis C-Related Deaths 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: